Clinical trials: Normal Skin
Rheumatoid Arthritis
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
The objective of the current study is to assess the immunogenicity and safety of transitioning subjects with RA to DRL_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.
- Trial name
- RI-01-007 (NCT04268771)
- Testing
- Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
- Where
- 26 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Rheumatoid Arthritis
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe…
- Trial name
- NCT01254331
- Testing
- tocilizumab [RoActemra]
- Where
- 6 sites in Tunisia
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus, SLE
JBT-101 in Systemic Lupus Erythematosus (SLE)
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE).
- Conditions
- Systemic Lupus Erythematosus, SLE, Lupus
- Trial name
- NCT03093402
- Testing
- JBT-101
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatic Diseases
Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice
This study will examine the impact of providing patient-reported outcomes measurement information system (PROMIS) scores to patients before appointments with their healthcare provider.
- Trial name
- NCT05026853
- Testing
- PRO Integration into Clinical Practice
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Michigan
Keratoconus, Ocular Surface Disease
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE…
- Conditions
- Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia
- Trial name
- NCT04649177
- Testing
- Ocular surface optical coherence tomography
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Boston Sight
Rheumatoid Arthritis
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.
- Trial name
- NCT04512001
- Testing
- MSB11456, EU-approved RoActemra
- Where
- 85 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 604 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to…
- Trial name
- NCT00650767
- Testing
- ARRY-438162, MEK inhibitor; oral
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 201 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Breast Cancer, Breast Neoplasm
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive…
- Trial name
- NCT01466972
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hope Rugo, MD
Angioedema
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who…
- Trial name
- NCT04444895
- Testing
- Lanadelumab
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 73 people
- Sponsor
- Shire
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
- Trial name
- NCT00521339
- Testing
- Apremilast
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amgen
Melanoma, Advanced Melanoma
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04695977
- Testing
- CMP-001, Nivolumab
- Where
- 20 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Lower Extremity or Diabetic Foot Ulcers, Bacterial Infection
Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm
This is a prospective study of Veterans with chronic lower extremity or diabetic foot ulcers who will be randomized to either a Larval Debridement Therapy group (Biobags every 4 days x 2 applications) or a Sharp Debridement…
- Trial name
- NCT02294175
- Testing
- Larval Debridement Therapy, Bedside Sharp Debridement
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- North Florida Foundation for Research and Education
Breast Cancer
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00041067
- Testing
- filgrastim, trastuzumab, docetaxel
- Where
- 145 sites in United States
- Volunteers
- 76 people
- Sponsor
- SWOG Cancer Research Network
Abscess
Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
The purpose of the study is to compare rates of cure of abscesses with and without antibiotic treatment after incision and drainage.
- Trial name
- NCT00691600
- Testing
- oral trimethoprim/sulfamethoxazole
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Healthy Study Participants, Impaired Hepatic Function
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.
- Trial name
- NCT04136444
- Testing
- Padsevonil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Breast Cancer
89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
- Trial name
- NCT02065609
- Testing
- 89Zr-Trastuzumab Human Dosimetry and Safety, HER2 Positive Lesion Detection and Safety
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Osteoarthritis, Rheumatoid Arthritis
Exceed ABT Acetabular Cup Cementless System
A Post-market Clinical Follow-up Study to provide safety, performance and clinical benefits data on the Exceed ABT acetabular cup (implants and instruments) when used in combination with ceramic liners or polyethylene…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Correction of Functional Deformity
- Trial name
- NCT04255394
- Volunteers
- 677 people
- Sponsor
- Zimmer Biomet
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Xerostomia, Sjogren Syndrome
Green Tea Lozenges for the Management of Dry Mouth
The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia.
- Conditions
- Xerostomia, Sjogren Syndrome, Dry Mouth
- Trial name
- NCT01647737
- Testing
- MighTeaFlow, Xylitol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.